Skip Navigation


Briefings in Functional Genomics and Proteomics Advance Access originally published online on October 4, 2007
Briefings in Functional Genomics and Proteomics 2007 6(3):193-201; doi:10.1093/bfgp/elm023
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
6/3/193    most recent
elm023v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Asslaber, M.
Right arrow Articles by Zatloukal, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Asslaber, M.
Right arrow Articles by Zatloukal, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press, 2007, All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Special Issue Papers

Biobanks: transnational, European and global networks

Martin Asslaber and Kurt Zatloukal

Corresponding author. Kurt Zatloukal, Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25, A-8036 Graz, Austria. Tel: +43-316-380-4404; Fax: +43-316-384-329; E-mail: kurt.zatloukal{at}meduni-graz.at

Biobanks contain biological samples and associated information that are essential raw materials for advancement of biotechnology, human health, and research and development in life sciences. Population-based and disease-oriented biobanks are major biobank formats to establish the disease relevance of human genes and provide opportunities to elucidate their interaction with environment and lifestyle. The developments in personalized medicine require molecular definition of new disease subentities and biomarkers for identification of relevant patient subgroups for drug development. These emerging demands can only be met if biobanks cooperate at the transnational or even global scale. Establishment of common standards and strategies to cope with the heterogeneous legal and ethical landscape in different countries are seen as major challenges for biobank networks. The Central Research Infrastructure for Molecular Pathology (CRIP), the concept for a pan-European Biobanking and Biomolecular Resources Research Infrastructure (BBMRI), and the Organization for Economic Co-operation and Development (OECD) global Biological Resources Centres network are examples for transnational, European and global biobank networks that are described in this article.

Keywords: biobank, personalized medicine, biomarkers, CRIP, ESFRI, OECD Biological Resource Centres


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ScienceHome page
D. Gurwitz, I. Fortier, J. E. Lunshof, and B. M. Knoppers
Children and Population Biobanks
Science, August 14, 2009; 325(5942): 818 - 819.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. EthicsHome page
B Hofmann
Broadening consent--and diluting ethics?
J. Med. Ethics, February 1, 2009; 35(2): 125 - 129.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.